This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.

NCT00531440 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

256

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Transplantation

Interventions

DRUG: Everolimus (RAD001)

Sponsor

Novartis Pharmaceuticals